PensionDanmark Pensionsforsikringsaktieselskab Has $5.12 Million Position in West Pharmaceutical Services, Inc. $WST

PensionDanmark Pensionsforsikringsaktieselskab increased its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 14.4% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 14,260 shares of the medical instruments supplier’s stock after acquiring an additional 1,800 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in West Pharmaceutical Services were worth $5,119,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Empowered Funds LLC raised its position in West Pharmaceutical Services by 16.1% in the 1st quarter. Empowered Funds LLC now owns 1,611 shares of the medical instruments supplier’s stock valued at $361,000 after buying an additional 224 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of West Pharmaceutical Services by 27.7% in the first quarter. Intech Investment Management LLC now owns 6,020 shares of the medical instruments supplier’s stock valued at $1,348,000 after purchasing an additional 1,307 shares during the last quarter. Acadian Asset Management LLC raised its holdings in shares of West Pharmaceutical Services by 14.1% in the first quarter. Acadian Asset Management LLC now owns 1,271 shares of the medical instruments supplier’s stock valued at $284,000 after purchasing an additional 157 shares during the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of West Pharmaceutical Services by 78.2% in the second quarter. EverSource Wealth Advisors LLC now owns 449 shares of the medical instruments supplier’s stock worth $98,000 after purchasing an additional 197 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in West Pharmaceutical Services by 168.4% during the second quarter. First Trust Advisors LP now owns 46,332 shares of the medical instruments supplier’s stock worth $10,137,000 after purchasing an additional 29,067 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Wall Street Analyst Weigh In

WST has been the subject of a number of analyst reports. KeyCorp raised their target price on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “overweight” rating in a research report on Thursday, July 2nd. Stephens restated an “overweight” rating and set a $360.00 price objective on shares of West Pharmaceutical Services in a research note on Tuesday, June 2nd. BNP Paribas Exane initiated coverage on West Pharmaceutical Services in a research report on Monday, July 13th. They issued an “outperform” rating and a $447.00 target price on the stock. Zacks Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a report on Wednesday, May 13th. Finally, Weiss Ratings raised West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $368.08.

West Pharmaceutical Services Stock Performance

WST opened at $353.61 on Monday. The company has a quick ratio of 2.12, a current ratio of 2.82 and a debt-to-equity ratio of 0.07. West Pharmaceutical Services, Inc. has a 12-month low of $223.83 and a 12-month high of $386.00. The business has a 50 day moving average of $342.97 and a 200-day moving average of $292.48. The stock has a market cap of $24.89 billion, a price-to-earnings ratio of 45.28, a PEG ratio of 2.47 and a beta of 1.15.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 23rd. The medical instruments supplier reported $2.37 earnings per share for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. During the same period in the previous year, the firm earned $1.84 EPS. The firm’s revenue was up 13.8% compared to the same quarter last year. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, equities research analysts expect that West Pharmaceutical Services, Inc. will post 8.94 earnings per share for the current year.

West Pharmaceutical Services Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were given a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 annualized dividend and a dividend yield of 0.2%. West Pharmaceutical Services’s dividend payout ratio is presently 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.